Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-692 in Schizophrenia
NCT04158687Phase 2Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deutarserine in schizophrenia (4 arms), sponsored by Concert Pharmaceuticals. Primary endpoint: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
deutarserine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04158687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158687.